Signal: AbbVie ends multi-million dollar cancer drug deal with I-Mab
Biopharma giant AbbVie has announced it intends to terminate its cancer drug deal with I-Mab, the creators of lemzoparlimab. The…
AbbVie
-
-
Tolero Pharmaceuticals and AbbVie partner to develop AML therapy
Biopharmaceutical firm Tolero Pharmaceuticals and AbbVie have formed a clinical research alliance to evaluate venetoclax and alvocidib combination for relapsed…
-
AbbVie signs patent licensing deal with Mylan over Humira biosimilar
AbbVie has entered patent licence agreements with Mylan for the proposed biosimilar product of its Humira (adalimumab) drug. Adalimumab is…
-
AbbVie submits venetoclax sNDA for acute myeloid leukaemia
AbbVie has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for the use…
